The Defense Advanced Research Projects Agency (DARPA) is hosting a Technology Exchange Workshop next week to discuss the DARPA Dialysis-Like Therapeutics (DLT) program. The goal of DLT is to develop a portable device that removes “dirty” blood from the body, separates harmful agents, and returns “clean” blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine, the target application for this device is sepsis.
The envisioned system will be capable of removing at least 90% of unknown pathogens, cytokines, toxins, and activated cells from a patient in one day with the objective of significantly reducing patient mortality. At the completion of the program the device will be submitted to the Food and Drug Administration (FDA) for possible Investigational Device Exemption (IDE) status.
The objective of the workshop will be to familiarize interested parties with the DLT component technologies, discuss potential scientific requirements for integration proposals, and examine award instrument types and funding options for the forthcoming Integration Broad Agency Announcement (BAA) anticipated in early April 2012. Such events further allow companies to discuss possible teaming synergies in advance which can result in more comprehensive responses to the BAA.
The event will be held on Thursday, March 29, 2012 in Arlington, VA. Further details are available under DARPA Solicitation DARPA-SN-12-05.
